Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 07BANGKOK1269, RTG DEFENDS COMPULSORY LICENSES, INDUSTRY CONSIDERS

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #07BANGKOK1269.
Reference ID Created Released Classification Origin
07BANGKOK1269 2007-03-04 23:45 2011-08-25 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Bangkok
VZCZCXRO4563
RR RUEHCHI RUEHDT RUEHHM RUEHNH
DE RUEHBK #1269/01 0632345
ZNR UUUUU ZZH
R 042345Z MAR 07
FM AMEMBASSY BANGKOK
TO RUEHC/SECSTATE WASHDC 5236
RUCNASE/ASEAN MEMBER COLLECTIVE
RUEHGV/USMISSION GENEVA 1786
RUCPDOC/USDOC WASHINGTON DC
RUEAHLC/HQS DHS WASHDC
UNCLAS SECTION 01 OF 02 BANGKOK 001269 
 
SIPDIS 
 
SENSITIVE 
 
SIPDIS 
 
STATE PASS USTR FOR B. WEISEL, C. WILSON 
STATE PASS USPTO 
HHS/OHGA FOR AMAR BHAT, ERIKA ELVANDER 
USDOC FOR JKELLY 
 
E.O. 12958:N/A 
TAGS: ECON ETRD KIPR TH
SUBJECT:  RTG DEFENDS COMPULSORY LICENSES, INDUSTRY CONSIDERS 
OPTIONS 
 
1.  (U) Summary:  The RTG issued a white paper defending its use of 
compulsory licenses and stated that it will continue their use. 
Industry attempted to open a dialogue with the Ministry of Public 
Health to head off future actions, but met antagonism by health 
officials who hold the industry in low regard.  Officials were 
interested in little that industry could offer other than lower 
prices for their products.  Companies affected by the compulsory 
licenses are still considering what legal options are available to 
challenge their issuance, but have otherwise hit a dead end on how 
else to proceed.  Public health officials have lost none of their 
fervor for compulsory licenses, but it is unclear they will be able 
to push future licenses through the cabinet.  End Summary. 
 
2.  (U) On February 16, the RTG Ministry of Public Health (MoPH) 
released an 80-page white paper explaining their decision to issue 
compulsory licenses to override patents on three pharmaceutical 
products in Thailand.  The paper justified the actions on the RTG's 
limited health budget and the need to ensure access for Thai 
patients to all drugs on the country's National List of Essential 
Medicines (NLEM).  The paper states that compulsory licenses will 
continue and sets out three criteria for choosing medicines:  1) 
drugs must be on the NLEM; 2) must be necessary for solving a health 
problem in the country; and 3) have a very high price (undefined). 
The government will pay royalties of .5 or two percent of sales for 
drugs of high and low volume, respectively. 
 
3.  (U) A MoPH report to the Prime Minister identified ten other 
drugs that the Ministry has considered for future CLs, including two 
antibiotics and eight drugs to treat heart disease and cancer.  Some 
press reports mentioned consideration of Bristol-Myers Squibb's 
antiretroviral atazanavir as well, though the drug is not listed on 
the NLEM and would presumably therefore not be eligible.  The report 
gave no timeline for any future CLs and it is not clear how 
thoroughly the Ministry reviewed the list of potential CLs.  Several 
of the drugs listed have expired patents, and at least one was never 
patented in Thailand. 
 
4.  (U) The local pharmaceutical association, Prema, met with MoPH 
Minister Mongkol Na Songkhla on February 19 and presented a proposal 
for a joint committee between Prema and MoPH that they dubbed the 
Thailand Health Access Initiative (THAI) Consultative Forum.  For 
anti-trust reasons the committee would not discuss pricing, but 
could discuss technology transfer issues and philanthropic 
activities to work on neglected diseases, donate medicines and 
improve delivery to difficult to reach areas of Thailand.  Prema 
said the revocation of CLs would not be a condition for 
establishment of the committee, but would be an item for 
consideration. 
 
5.  (U) MoPH roundly rejected the idea and participants in the 
meeting said they were shocked by how vehemently the Minister 
reacted.  MoPH officials present blasted the proposal as little more 
than a delaying tactic and insisted the only proposal they would 
accept from industry would be a list of which drugs they would 
reduce the price and by how much.  Dr. Mongkol roundly criticized 
the industry as a whole.  The Minister was reportedly an 
enthusiastic reader of a recent anti-pharma book, "The Truth about 
the Drug Companies", and frequently cites arguments from the book to 
justify the CLs.  In a press interview, Dr. Mongkol conceded that 
last year's coup gave him the chance to act, and that a "true 
politician" would not have pursued his CL policy, fearing the 
consequences.  Mongkol continued, "I am not a politician, and I have 
nothing to lose." 
 
RTG walling itself off 
---------------------- 
 
6.  (U) The Ministry of Commerce rebuffed an Embassy request for 
Ambassador Boyce to meet with Minister Krirk-krai to deliver a 
letter from Commerce Secretary Gutierrez regarding CLs.  In the end, 
Econ Counselor and Commercial Counselor met with Deputy DG Srivicha 
Rackchamroon, who politely agreed that economic times were in fact 
difficult, but had little else to say. 
 
7.  (SBU) EU representatives are requesting Brussels' approval for a 
demarche on the CL issue.  Proposed points express the EU's surprise 
that CLs were extended to products beyond those used for epidemics 
and seeks clarification on Thai policy, including the types of 
medicines/diseases that would be covered by CLs, the duration of the 
use of CLs and the circumstances which justified their use.  The 
points also express concerns over the lack of consultation with 
industry.  Unfortunately, MOPH informed the EU that Dr. Mongkol 
 
BANGKOK 00001269  002 OF 002 
 
 
would be busy for the entire month of March; the Ministry of 
Commerce has yet to respond to their appointment request either. 
For their part, the Swiss Embassy has taken no action and has no 
plans to do so, citing an absence of complaints from Swiss 
pharmaceutical companies. 
 
8.  (U) Industry was briefly buoyed by reports that WHO Director 
Margaret Chan had criticized Thailand's CL policy, telling the press 
after a meeting with Dr. Mongkol that there had to be a right 
balance for compulsory licensing.  However, only days later Chan 
wrote Mongkol that the WHO supported the use of TRIPS flexibilities, 
and clarified that her statements should not be taken as a criticism 
of the RTG's decision, though she believed industry was still part 
of the solution to high health costs. 
 
Companies mull their legal options 
---------------------------------- 
 
9.  (SBU) Merck & Co., whose antiretroviral efavirenz was hit by a 
CL last November, filed an appeal with the Department of 
Intellectual Property on February 12, challenging the RTG decision. 
The press has reported that the appeal was rejected, but Merck has 
yet to receive an official response.  Although still considering 
themselves in talks with the RTG, they are not hopeful for a 
negotiated resolution.  Merck says they delivered their final offer 
to MoPH on February 6, offering a price still above that of the 
comparable generic.  They have received no formal response.  MoPH's 
white paper revealed that generic efavirenz has been certified and 
registered with the Thai FDA and the first order has already entered 
the country, though Merck says they have not seen generic product 
enter distribution channels.  The Government Pharmaceutical 
Organization (GPO) recently contacted Merck regarding payment of 
royalties for the purchases. 
 
10.  (SBU) Abbott Labs, target of a January CL /n their 
antiretroviral Kaletra, has yet to make a final decision on whether 
to take legal action.  In contrast to Merck, Abbott has yet to 
proffer a reduction in price to head off the CL and has not actively 
pursued negotiations.  Abbott's lawyers are prepared to file a 
series of appeals with the Ministry of Public Health's Department of 
Disease Control, the actual isster of the CL on Kaletra.  If the 
appeals are unsuccessful, Abbott could then bring a case to the 
Intellectual Property court to determine the CL's legality. 
 
11.  (SBU) Paris-based Sanofi-Aventis, maker of the anti-clotting 
agent Plavix and another target of a CL, has also declined to 
negotiate and has not offered a reduction in price.  Sanofi has yet 
to take legal measures but consider all options to be open at this 
time. 
 
Purging GPO 
----------- 
 
12.  (U) On February 28, the RTG cabinet dismissed GPO Managing 
Director Mongkol Jivasantikarn, in part because of an apparent lack 
of enthusiasm for GPO's role in issuing CLs and producing generic 
versions.  Press reports cited a personal row with GPO board 
chairman Vichai Chokewiwat, a vocal booster of CLs within the RTG. 
Vichai declined to disclose the reasons for Mongkol's dismissal, 
noting only that the decision had been approved by GPO's directors. 
Industry reps say that MOPH officials considered the GPO Director to 
be a holdover from the previous administration and had been seeking 
a reason to oust him. 
 
13.  (U) Comment:  Industry has thus far been unable to coordinate a 
common approach to the RTG's CL policy and actions have been 
haphazard.  Efforts by individual companies to negotiate or 
challenge the CLs have not produced results, and the tentative 
attempts to approach the RTG as an industry have met with outright 
hostility.  MoPH officials have lost none of their ardor for CLs, 
but it is unclear whether the rest of the RTG has the stomach for 
yet more controversial economic decisions.  Top RTG officials have 
mentioned that any future CL decision be considered first by the 
cabinet, and approval is not assured.  After a long series of 
economic missteps and the recent high-profile resignation of Deputy 
PM Pridiyathorn, cabinet officials may be more interested in keeping 
controversy to a minimum.  End Comment.